| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22067 |
| Drug |
Bulevirtide |
| Brand |
Hepcludex® |
| Indication |
Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease. |
| Rapid review commissioned |
06/10/2022 |
| Rapid review completed |
10/11/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bulevirtide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/11/2022 |
| Pre-submission consultation with Applicant |
10/01/2023 |
| Full submission received from Applicant |
06/09/2023 |
